ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Two activists Are Appointed To Complete NCAB

May 31, 1991

House Members Form Group To Address Cancer Policy.

February 23, 2001

Agency Approves Two Pairs Of Drugs and Diagnostic Tests

September 30, 2011

Legislation Would Create Medicare Service For Comprehensive Cancer Care planning.

May 26, 2006

NCI Revises Procedure for Contract Concept Review By Advisors

September 6, 1996

DeVita Frustrated By Gap Between Bypass, “Real” Budgets, Seeks Better System To Develop Priorites

April 24, 1981